US equities
|
SPCX
$167.16
▲+5.16%
NVDA
$237.10
▲+1.35%
MU
$1,063.99
▼-1.01%
TSLA
$377.74
▲+1.93%
MSFT
$526.30
▲+1.70%
INTC
$116.76
▼-2.15%
SNDK
$1,712.99
▼-0.41%
META
$745.25
▲+2.36%
SPCX
$167.16
▲+5.16%
NVDA
$237.10
▲+1.35%
MU
$1,063.99
▼-1.01%
TSLA
$377.74
▲+1.93%
MSFT
$526.30
▲+1.70%
INTC
$116.76
▼-2.15%
SNDK
$1,712.99
▼-0.41%
META
$745.25
▲+2.36%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Neurocrine Biosciences, Inc. - Common Stock
(NQ:
NBIX
)
145.47
+2.29 (+1.60%)
Delayed Quote
Updated: 11:19 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Neurocrine Biosciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Neurocrine Biosciences (NASDAQ:NBIX) Stands Out as a Decent Value Stock
↗
Today 7:51 EDT
Via
Chartmill
Neurocrine Biosciences (NASDAQ:NBIX): Affordable Growth at a Reasonable Valuation
↗
October 02, 2026
Via
Chartmill
Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit
↗
September 23, 2026
Neurocrine Biosciences (NASDAQ:NBIX) outlined its commercial growth priorities, pricing considerations and pipeline plans during a Morgan Stanley discussion, with CEO Kyle Gano emphasizing the...
Via
MarketBeat
Topics
Artificial Intelligence
Neurocrine Biosciences (NASDAQ:NBIX): An Affordable Growth Stock With Strong Momentum and Valuation
↗
August 29, 2026
Via
Chartmill
Neurocrine Biosciences (NASDAQ:NBIX): A Value Stock With Quality Behind the Discount
↗
August 05, 2026
Via
Chartmill
Neurocrine (NBIX) Q2 2026 Earnings Call Transcript
↗
August 03, 2026
Revenue hit $950 million as INGREZZA surged 15% and CRENESSITY grew 20%.
Via
The Motley Fool
Topics
Earnings
Neurocrine Biosciences (NASDAQ:NBIX): Strong Growth Stock with Technical Breakout Setup
↗
July 27, 2026
Via
Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High Growth Stock
↗
July 25, 2026
Via
Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Offers a High Growth Momentum Breakout Setup
↗
July 20, 2026
Via
Chartmill
Neurocrine Biosciences Q2 Earnings Call Highlights
↗
July 31, 2026
Neurocrine Biosciences (NASDAQ:NBIX) reported second-quarter 2026 revenue of more than $950 million, nearly 40% higher than a year earlier, as sales of INGREZZA and CRENESSITY continued to grow and the...
Via
MarketBeat
Topics
Earnings
Neurocrine (NBIX) Q2 2026 Earnings Call Transcript
↗
July 30, 2026
Revenue hit $950 million as INGREZZA surged 15% and CRENESSITY grew 20%.
Via
The Motley Fool
Topics
Earnings
Neurocrine Biosciences (NASDAQ:NBIX) Fits the Growth at a Reasonable Price Mold of Peter Lynch Screening
↗
July 16, 2026
Via
Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Scores High in Affordable Growth Screen
↗
July 11, 2026
Via
Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shines in the "Little Book That Makes You Rich" Screen
↗
July 04, 2026
Via
Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Growth and Technical Breakout Setup
↗
July 01, 2026
Via
Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Fits the Profile of a Classic GARP Stock Under the Peter Lynch Framework
↗
June 24, 2026
Via
Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Decent Value Play with Strong Fundamentals
↗
June 20, 2026
Via
Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High-Growth Momentum Breakout Candidate
↗
June 16, 2026
Via
Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Growth Stock Pick from the Little Book Strategy
↗
June 10, 2026
Via
Chartmill
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Nears Technical Breakout with Near-Perfect Score
↗
June 08, 2026
Via
Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Peter Lynch GARP Opportunity with Strong Growth and a PEG Ratio of 0.82
↗
June 03, 2026
Via
Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Fundamentals and Bull Flag Breakout Setup
↗
May 29, 2026
Via
Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High Growth Momentum Breakout Setup
↗
May 26, 2026
Via
Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Shows Affordable Growth Potential
↗
May 22, 2026
Via
Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Value Gem With Solid Fundamentals
↗
May 19, 2026
Via
Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a Peter Lynch-Style GARP Opportunity
↗
May 12, 2026
Via
Chartmill
Neurocrine (NBIX) Q1 2026 Earnings Transcript
↗
May 05, 2026
Neurocrine (NBIX) Q1 2026 Earnings Transcript
Via
The Motley Fool
Neurocrine Biosciences (NASDAQ:NBIX) Smashes Q1 Estimates with 44% Sales Surge
↗
May 05, 2026
Via
Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Qualifies for Affordable Growth Screen with Strong GARP Profile
↗
April 30, 2026
Via
Chartmill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
May 05, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
